OnTrackCF: Using a smartphone app to help manage CF treatment
Part of Digestive system, Genetic & congenital, Lungs & breathing clinical trials.
This study tests a smartphone app designed to help people with cystic fibrosis stay on track with their twice-daily CFTR modulator medication. Researchers want to see if the app is easy to use and helpful.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a diagnosis of cystic fibrosis (CF).
- You are 18 years old or older.
- You have been prescribed a CFTR modulator medication (like Trikafta, Symdeko, or Orkambi) that you take twice a day.
- You can speak and read English.
- You have regular access to a smartphone or tablet with internet (iPhone or Android).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether people with cystic fibrosis who are already on a triple combination CFTR modulator can stay on their treatment without interruptions or problems. It aims to make sure everyone gets the best, most consistent treatment for their CF.
This study tests a personalized smartphone app to help teens and young adults with cystic fibrosis be more active. The app provides tailored tips and support to encourage daily physical activity.
This study tests a fun mobile app designed to help children and teens with cystic fibrosis do their daily airway clearance exercises. If your child is between 8 and 20 years old and has CF, they might be able to join and possibly make breathing treatments more enjoyable.
This study tests new treatments for cystic fibrosis in people who cannot take or choose not to take current CFTR modulators. It aims to find better options for managing CF.
This early study tests an individualized approach (“theratyping”) to match your cystic fibrosis (CF) to the CFTR medicine that may work best for your specific genetic change. It may help find a more tailored treatment plan and see how your body responds, while using medicines that are already approved for some people with CF.
This Phase 2 trial tests 4D-710 to improve lung health in adults with cystic fibrosis who either cannot take CFTR modulator medicines or are not doing well enough on them. You may be eligible if you have moderate lung function and stable oxygen levels, and you meet other safety and health requirements.
Hear when a new Cystic Fibrosis (CF) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.